APIMEDS PHARMACEUTICALS US, INC. Interest Expense Nonoperating
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Interest Expense Nonoperating of $3.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $3.22M, a 13883.50% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $859.40K, a 2159.69% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $215.62K, a 498.12% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $6.30K, a 80.69% decline year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. interest expense nonoperating for fiscal 2025 was $283.01K, a 140.41% increase from fiscal 2024.
- APIMEDS PHARMACEUTICALS US, INC. interest expense nonoperating for fiscal 2024 was $117.72K, a 209.23% increase from fiscal 2023.
- APIMEDS PHARMACEUTICALS US, INC. interest expense nonoperating for fiscal 2023 was $38.07K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.22M 10-Q · filed 2026-08-14 | $4.08M 10-Q · filed 2026-08-14 | $4.30M derived: sum of 3 quarters · filed 2026-08-14 | $4.31M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $859.40K 10-Q · filed 2026-05-26 | $1.08M derived: sum of 2 quarters · filed 2026-05-26 | $1.08M derived: sum of 3 quarters · filed 2026-05-26 | $1.10M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $215.62K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $221.93K derived: sum of 2 quarters · filed 2026-05-04 | $244.98K derived: sum of 3 quarters · filed 2026-08-14 | $283.01K 10-K · filed 2026-05-04 |
| 2025-09-30 | $6.30K 10-Q · filed 2025-11-12 | $29.36K derived: sum of 2 quarters · filed 2026-08-14 | $67.39K 10-Q · filed 2025-11-12 | $103.44K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $23.05K 10-Q · filed 2026-08-14 | $61.09K 10-Q · filed 2026-08-14 | $97.14K derived: sum of 3 quarters · filed 2026-08-14 | $129.77K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $38.03K 10-Q · filed 2026-05-26 | $74.08K derived: sum of 2 quarters · filed 2026-05-26 | $106.72K derived: sum of 3 quarters · filed 2026-05-26 | $128.84K derived: sum of 4 quarters · filed 2026-05-26 |
| 2024-12-31 | $36.05K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $68.69K derived: sum of 2 quarters · filed 2026-05-04 | $90.81K derived: sum of 3 quarters · filed 2026-05-04 | $117.72K 10-K · filed 2026-05-04 |
| 2024-09-30 | $32.64K 10-Q · filed 2025-11-12 | $54.76K derived: sum of 2 quarters · filed 2025-11-12 | $81.67K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $22.12K 10-Q · filed 2025-08-19 | $49.03K 10-Q · filed 2025-08-19 | ||
| 2024-03-31 | $26.91K 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | $38.07K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |